MacroGenics Inc (MGNX) Drops 5.67% on January 18

Equities Staff |

MacroGenics Inc (MGNX) was one of the Russell 2000's biggest losers for Monday January 18 as the stock slid 5.67% to $22.44, a loss of $-1.35 per share. Starting at an opening price of $22.58 a share, the stock traded between $21.84 and $23.76 over the course of the trading day. Volume was 266,071 shares over 3,633 trades, against an average daily volume of 320,044 shares and a total float of 34.31 million.

The losses send MacroGenics Inc down to a market cap of $769.97 million. In the last year, MacroGenics Inc has traded between $39.90 and $19.67, and its 50-day SMA is currently $30.98 and 200-day SMA is $31.22.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

MacroGenics Inc is based out of Rockville, MD and has some 211 employees. Its CEO is Scott Koenig.

For a complete fundamental analysis analysis of MacroGenics Inc, check out’s Stock Valuation Analysis report for MGNX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Lithium-X Energy Corp.

Lithium X Energy Corp is engaged in exploring and developing lithium resources. Its projects portfolio includes Albemarle's Silver Peak brine evaporation pond project.

Private Markets


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…


Wealthfront is an automated investment service that serves as an alternative to traditional financial advisory services. The company manages a diversified, continually rebalanced portfolio of index funds on their clients’…